The study did not demonstrate a statistically significant improvement on the primary endpoint of change from baseline in the Montgomery-Asberg Depression Rating Scale total score at Week 6 or the key secondary endpoint of a change from baseline in the Snaith-Hamilton Pleasure Scale scale.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NMRA:
- Neumora Therapeutics’ navacaprant did not meet primary endpoint in depression
- Neumora: KOASTAL-1 study did not demonstrate SS improvement on primary endpoint
- Neumora Therapeutics Inc put volume heavy and directionally bearish
- J&J trial news may have positive read for Neumora Therapeutics, says RBC Capital
- Neumora Therapeutics Reports Q3 2024 Financial Results